NRAS and primary cutaneous T-cell non-Hodgkin lymphoma: Therapy of cutaneous T cell lymphoma (CTCL) is complicated by a distinct resistance of the malignant T cells towards apoptosis that can be caused by NRAS mutations in late-stage patients.